BioNano Genomics Inc vs Comfort Systems USA Inc — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Comfort Systems USA Inc trades at $1,786.5 (market cap $62.49B). The key difference: Comfort Systems USA Inc is far larger — about 4734.1× BioNano Genomics Inc's market cap, and Comfort Systems USA Inc pays a 0.15% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | FIX | |
|---|---|---|
Market Cap | $13.20M | $62.49B |
Sector | Health | Technology |
52-Week High | $4.92 | $2.07K |
52-Week Low | $1.09 | $532.14 |
Enterprise Value | $15.81M | $61.78B |
Dividend Yield | — | 0.15% |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Comfort Systems USA (FIX) trades at $1,732.03, down 1.37% on the day, amid a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings expectations with Q1 2026 EPS of $10.51 versus $6.81 expected, driven by robust revenue growth and a 12.07% net income margin. Recent news highlights the company's expansion in modular capabilities and leadership in AI infrastructure demand, with a record backlog supporting future growth.
The stock presents a compelling growth story with strong earnings momentum and analyst consensus pointing to significant upside (price target $2,100), but faces risks from execution challenges on its record backlog and premium valuation multiples (P/E 51.24). Investors should weigh the company's solid cash flow generation and market position against technical weakness and high expectations.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →